A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Assess Aesthetic Improvement and Onset of QM1114-DP Treatment Effect in Subjects With Moderate to Severe Glabellar Lines
Latest Information Update: 27 May 2024
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Glabellar lines
- Focus Registrational; Therapeutic Use
- Sponsors Galderma Research & Development; Q-Med
- 22 May 2024 Status changed from active, no longer recruiting to completed.
- 30 Nov 2023 According to Galdema pharma Media release, topline result was presented from this study.
- 30 Nov 2023 According to Galdema pharma Media release, primary endpoint ((Responders in QM1114-DP versus Placebo using the Global Aesthetic Improvement Scale (GAIS) at maximum frown at Month 1) has been met.